Genmab — April 2024
-
Sanofi Sarclisa Q1 '24 €106mn https://ml-eu.globenewswire.com/Resource/Download/ca345f70-58d6-4aa7-a4b1-8b6b43551051
-
this may be useful for future
Congress Presentations - hint you are a US healthcare professional
https://www.genmabmedicalaffairs.com/congress -
new trial - A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Recurrent/Metastatic Head and Neck Cancer (OrigAMI-4) https://clinicaltrials.gov/study/NCT06385080
-
Kort video..Der er kommet Q1-regnskab fra flere amerikanske selskaber. Bl.a. Tesla, IBM og Meta. Fedmeaktierne Novo Nordisk, Eli Lilly og Zealand Pharma falder efter kritik i USA af prissætningen på fedmeprodukter. Genmab falder også, efter to banker sænker kursmålet. https://www.proinvestor.com/boards/120115/
-
-
On 25 April 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Rybrevant. PAPILLON -amivantamab in combination with carboplatin and
pemetrexed for the first-line treatment https://www.ema.europa.eu/en/medicines/human/variation/rybrevant -
tisotumab vedotin submission in japan
https://genmab.co.jp/pressrelease/
det gode ved aktien er faldet så meget er at den jo så også kan stige meget Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind